Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epclusa for Hepatitis C in Transfusion-Dependent Thalassemia
NCT03032666Phase 4Completed
- Start
- May 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sofosbuvir + velpatasvir in hepatitis C (HCV). Primary endpoint: Sustained Viral Response at 12 weeks. Started May 2017; status: completed.
02
Drugs
sofosbuvir + velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03032666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03032666.